Age-specific prevalence for mf or LF antigen in Dokan Tofa and Piapung sentinel villages. Frank O. Richards Abel Eigege Emmanuel S. Miri Alphonsus Kal John Umaru Davou Pam Lindsay J. Rakers Yohanna Sambo Jacob Danboyi Bako Ibrahim Solomon E. Adelamo Gladys Ogah Danjuma Goshit O. Kehinde Oyenekan Els Mathieu P. Craig Withers Yisa A. Saka Jonathan Jiya Donald R. Hopkins 10.1371/journal.pntd.0001346.g007 https://plos.figshare.com/articles/figure/_Age_specific_prevalence_for_mf_or_LF_antigen_in_Dokan_Tofa_and_Piapung_sentinel_villages_/396500 <p>Panel A: Dokan Tofa pretreatment prevalence by age group (n = 418). Panel B: Piapung pretreatment prevalence by age group (n = 400). Panel C: Dokan Tofa prevalence by age group after 6 rounds of MDA (n = 223). Panel D: Piapung prevalence by age group after 6 rounds of MDA (n = 280). Boxes show numbers sampled in each age group. Pretreatment sample for mf is different from <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001346#pntd-0001346-t002" target="_blank">Table 2</a> because ages were not available on all persons tested. Pretreatment sample for antigen for these SVs are different than baseline figure shown in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001346#pntd-0001346-t003" target="_blank">Table 3</a> because 1999/2000 mapping data were added to baseline calculation in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001346#pntd-0001346-t003" target="_blank">Table 3</a> (see <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001346#s2" target="_blank">Methods</a>).</p> 2013-02-20 13:56:25 prevalence mf lf antigen dokan tofa piapung sentinel